Cassava Sciences's (SAVA) Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

Go back to Cassava Sciences's (SAVA) Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

Cassava Sciences (SAVA) Hits Low, Down 24%

February 4, 2021 2:29 PM EST

Cassava Sciences (NASDAQ: SAVA) Hits Low, Down 24%

... More

Cassava Sciences (SAVA) Extends Earlier Gain, Up Another 30%

February 3, 2021 5:05 PM EST

Cassava Sciences (NASDAQ: SAVA) Extends Earlier Gain, Up Another 30%

Closed up 59%
... More

Cassava Sciences (SAVA) Hits High, Up Over 30%

February 3, 2021 11:45 AM EST

Cassava Sciences (NASDAQ: SAVA) Hits High, Up Over 30%

... More

Cassava Sciences (SAVA) Extends Gain, Up 205%

February 2, 2021 1:58 PM EST

Cassava Sciences (NASDAQ: SAVA) Extends Gain, Up 205%

... More

Cassava Sciences (SAVA) to Resume Trading at 9 a.m.

February 2, 2021 8:35 AM EST

Cassava Sciences (NASDAQ: SAVA) to Resume Trading at 9 a.m.

... More